Dry eye disease (DED) is a condition characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. For 13 years, AbbVie’s Restasis was the only FDA-approved therapy for DED, until the launch of novel agents, including Bausch + Lomb’s Xiidra, Restasis MultiDose, Sun Ophthalmics’ Cequa, Alcon’s Eysuvis, and Viatris’s Tyrvaya. In addition, in May 2023, the FDA approved Bausch + Lomb / Novaliq’s Miebo, the first and only agent specifically approved to treat evaporative DED. Apart from conservative measures (e.g., lid hygiene, artificial tears), the management of DED also includes the prescription of off-label ophthalmic corticosteroids and antibiotics. This claims data analysis gives manufacturers of current treatments, as well as those developing novel agents, real-world insight into recent trends in the use of drugs for DED.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Bausch + Lomb, Sun Ophthalmics, Kala Pharmaceuticals, Alcon, Viatris, Novaliq
Key drugs: Restasis, Restasis MultiDose, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo
Key analysis provided